YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis

YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis

Abstract N6‐methyladenosine (m6A) modification orchestrates cancer formation and progression by affecting the tumor microenvironment (TME). For hepatocellular carcinoma (HCC), immune evasion and angiogenesis are characteristic features of its TME. The role of YTH N6‐methyladenosine RNA binding prote...

Full description

Bibliographic Details
Main Authors: Jingyuan Wen, Lin Xue, Yi Wei, Junnan Liang, Wenlong Jia, Tuying Yong, Liang Chu, Han Li, Shenqi Han, Jingyu Liao, Zeyu Chen, Yiyang Liu, Qiumeng Liu, Zeyang Ding, Huifang Liang, Lu Gan, Xiaoping Chen, Zhao Huang, Bixiang Zhang
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Advanced Science
Subjects:
angiogenesis
eIF3b
ETV5
immune evasion
Liver cancer
N6‐methyladenosine
Online Access:https://doi.org/10.1002/advs.202307242

Internet

https://doi.org/10.1002/advs.202307242

Similar Items